학술논문

18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery
Document Type
article
Source
Anesthesiology. 128(4)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Mental Health
Aging
Brain Disorders
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Behavioral and Social Science
Biomedical Imaging
Clinical Research
Neurosciences
Alzheimer's Disease
Dementia
Neurodegenerative
Acquired Cognitive Impairment
2.1 Biological and endogenous factors
Neurological
Aged
Amyloid beta-Peptides
Aniline Compounds
Brain
Cardiac Surgical Procedures
Cognitive Dysfunction
Ethylene Glycols
Female
Fluorine Radioisotopes
Humans
Male
Mental Status and Dementia Tests
Middle Aged
Positron-Emission Tomography
Postoperative Complications
Prospective Studies
Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study Group
Neurologic Outcomes Research Group
Anesthesiology
Clinical sciences
Language
Abstract
BackgroundAmyloid deposition is a potential contributor to postoperative cognitive dysfunction. The authors hypothesized that 6-week global cortical amyloid burden, determined by F-florbetapir positron emission tomography, would be greater in those patients manifesting cognitive dysfunction at 6 weeks postoperatively.MethodsAmyloid deposition was evaluated in cardiac surgical patients at 6 weeks (n = 40) and 1 yr (n = 12); neurocognitive function was assessed at baseline (n = 40), 6 weeks (n = 37), 1 yr (n = 13), and 3 yr (n = 9). The association of 6-week amyloid deposition with cognitive dysfunction was assessed by multivariable regression, accounting for age, years of education, and baseline cognition. Differences between the surgical cohort with cognitive deficit and the Alzheimer's Disease Neuroimaging Initiative cohorts (normal and early/late mild cognitive impairment) was assessed, adjusting for age, education, and apolipoprotein E4 genotype.ResultsThe authors found that 6-week abnormal global cortical amyloid deposition was not associated with cognitive dysfunction (13 of 37, 35%) at 6 weeks postoperatively (median standard uptake value ratio [interquartile range]: cognitive dysfunction 0.92 [0.89 to 1.07] vs. 0.98 [0.93 to 1.05]; P = 0.455). In post hoc analyses, global cortical amyloid was also not associated with cognitive dysfunction at 1 or 3 yr postoperatively. Amyloid deposition at 6 weeks in the surgical cohort was not different from that in normal Alzheimer's Disease Neuroimaging Initiative subjects, but increased over 1 yr in many areas at a rate greater than in controls.ConclusionsIn this study, postoperative cognitive dysfunction was not associated with 6-week cortical amyloid deposition. The relationship between cognitive dysfunction and regional amyloid burden and the rate of postoperative amyloid deposition merit further investigation.